Comparison of Safety and Efficacy of Warfarin Versus Rivaroxaban in Northern Chinese Patients With Different CHA2DS2-VASc Score

Abstract

Purpose: Although many researches have indicated the anticoagulant effect of warfarin and rivaroxaban in atrial fibrillation (AF) patients, the comparison of these drugs on safety and efficacy in northern Chinese patients with different CHA2DS2-VASc Score is unclear. We aim to compare the safety and efficacy of warfarin versus rivaroxaban in northern Chinese AF patients with different CHA2DS2-VASc Score subgroups. Methods: 387 AF patients were recruited in the study. Of these, one group patients (n=194) were receiving warfarin, and the other group patients (n=193) were receiving rivaroxaban. Follow-up data were collected for one year, which included adherence, bleeding and ischemic stroke (IS) events. Results: There was better adherence in rivaroxaban-treated group than warfarin-treated group. The events of bleeding decreased with increased score in warfarin-treated group. Patients with score 2-3, had better adherence and less stroke events in warfarin-treated group. The events of bleeding and stroke was not significantly different in rivaroxaban-treated group at different score. Conclusions: We found that there was better adherence and less bleeding and stroke events in rivaroxaban-treated group than warfarin-treated group with different CHA2DS2-VASc score. There is better choice for northern Chinese patients to select rivaroxaban in the anticoagulative treatment of AF, regardless of economic factors.